Pyoderma gangrenosum

Mount Sinai Journal of Medicine

Volumn 68, Issue 4-5, 2001, Pages 287-297

  Blitz, Neal M ^a   Rudikoff, Donald ^b  

^a Providence Seattle Medical Center   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Chemokines; Corticosteroids; Cyclosporine; Inflammatory bowel disease; Neutrophilic dermatoses; Pyoderma gangrenosum; Tacrolimus

Indexed keywords

CHEMOKINE; CORTICOSTEROID; CYCLOSPORIN; TACROLIMUS;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ARTHRITIS; CHRONIC HEPATITIS; DIFFERENTIAL DIAGNOSIS; ENTERITIS; IMMUNOSUPPRESSIVE TREATMENT; MYELOPROLIFERATIVE DISORDER; PROGNOSIS; PYODERMA GANGRENOSUM; REVIEW; SKIN ULCER;

ADRENAL CORTEX HORMONES; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; PYODERMA GANGRENOSUM;

EID: 0034894270     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Brunsting LA, Goeckerman WH, O'Leary PA. Pyoderma (ecthyma) gangrenosum: Clinical and experimental observations in five cases occurring in adults. Arch Dermatol Syphilol 1930; 22:655-680.
2. Bennett ML, Jackson JM, Jorizzo JL, et al. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore) 2000; 79:37-46.
3. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: A study of 700 patients. Medicine (Baltimore) 1976; 55:401-412.
4. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: A pathologic and clinical entity. JAMA 1932; 99:1323-1329. [Reprinted: Mt Sinai J Med 2000; 67:263-268.]
5. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: A pathologic and clinical entity. JAMA 1932; 99:1323-1329. [Reprinted: Mt Sinai J Med 2000; 67:263-268.]
6. Libin MR, Greenstein A, Bauer JJ. Pyoderma gangrenosum in Crohn's disease. Mt Sinai J Med 1983; 50:452-456.
7. Talansky AL, Meyers S, Greenstein AJ, Janowitz HD. Does intestinal resection heal the pyoderma gangrenosum of inflammatory bowel disease? J Clin Gastroenterol 1983; 5:207-210.
8. Keltz M, Lebwohl M, Bishop S. Peristomial pyoderma gangrenosum. J Am Acad Dermatol 1992; 27:360-364.
9. Freedman AM, Phelps RG, Lebwohl M. Pyoderma gangrenosum associated with anticardiolipin antibodies in a pregnant patient. Int J Dermatol 1997; 36:205-207.
10. Klein S, Mayer L, Present DH, et al. Extraintestinal manifestations in patients with diverticulitis. Ann Intern Med 1988; 108:700-702.
11. Hecker MS, Lebwohl MG. Recalcitrant pyoderma gangrenosum: Treatment with thalidomide. J Am Acad Dermatol 1998; 38:490-491.
12. Kitagawa N, Ikeda M, Kodama H. Acute form of pyoderma gangrenosum introduced by traumatic injury. J Dermatol 1996; 23:116-119.
13. Steadman UA, Brennan TE, Daman LA, Curry SL. Pyoderma gangrenosum following cesarean delivery. Obstet Gynecol 1998; 91:834-836.
14. Finkel SI, Janowitz HD. Trauma and the pyoderma gangrenosum of inflammatory bowel disease. Gut 1981; 22:410-412.
15. Gungor E, Karakayali G, Alli N, et al. Penile pyoderma gangrenosum. J Eur Acad Dermatol Venereol 1999; 12:59-62.
16. Farrell AM, Black MM, Bracka A, Bunker CB. Pyoderma gangrenosum of the penis. Br J Dermatol 1998; 138:337-340.
17. Callen JP. Pyoderma gangrenosum and related disorders. Adv Dermatol 1989; 4:51-65.
18. Snyder RA. Pyoderma gangrenosum involving the head and neck. Arch Dermatol 1986; 122:295-302.
19. Jackson RM, Duvic M. Pyoderma gangrenosum/Sweet's syndrome. In: Jordon RE, editor. Immunologic diseases of the skin. Norwalk (CT): Appleton & Lange; 1991.
20. Hickman JG. Pyoderma gangrenosum. Clin Dermatol 1983; 1:102-113.
21. Lazarus GS, Goldsmith LA, Rocklin RE, et al. Pyoderma gangrenosum, altered delayed hypersensitivity and polyarthritis. Arch Dermatol 1972; 105:46-51.
22. Norris DA, Weston WL, Thorne G, Humbert JR. Pyoderma gangrenosum. Abnormal monocyte function corrected in vitro with hydrocortisone. Arch Dermatol 1978; 114:906-911.
23. Schroder JM, Szperalski B, Koh CJ, Christophers E. IgA-associated inhibition of polymorphonuclear leukocyte chemotaxis in neutrophilic dermatoses. J Invest Dermatol 1981; 77:464-468.
24. Hostoffer RW, Krukovets I, Berger M. Increased Fc alpha R expression and IgA-mediated function on neutrophils induced by chemo-attractants. J Immunol 1993; 150:4532-4540.
25. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320:365-376.
26. Snyder RA. Pyoderma gangrenosum. In: Thiers BH, Dobson RL, editors. Pathogenesis of skin disease. New York: Churchill Livingstone; 1986.
27. Dantzig PI. Pyoderma gangrenosum [letter]. N Engl J Med 1975; 292:47-48.
28. Su WP, Schroeter AL, Perry HO, Powell FC. Histopathologic and immunopathologic study of pyoderma gangrenosum. J Cutan Pathol 1986; 13:323-330.
29. Powell FC, Schroeter AL, Su WP, Perry HO. Pyoderma gangrenosum: A review of 86 patients. Q J Med 1985; 55:173-186.
30. Ullman S, Halberg P, Howitz J. Deposits of complement and immunoglobulins in vessel walls in pyoderma gangrenosum. Acta Derm Venereol 1982; 62:340-341.
31. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 1999; 341:1817-1828.
32. Dallegri F, Otonello L. Tissue injury in neutrophilic inflammation. Inflamm Res 1997; 46:382-391.
33. Terui T, Ozawa M, Tagami H. Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis, psoriasis: A neutrophil-associated inflammation-boosting loop. Exp Dermatol 2000; 9:1-10.
34. Wang DZ, McCaffrey PG, Rao A. The cyclosporin-sensitive transcription factor NFATp is expressed in several classes of cells in the immune system. Ann N Y Acad Sci 1995; 766:182-194.
35. Thorat SP, Thatte UM, Pai N, Dahanukar SA. Inhibition of phagocytes by cyclosporin in vitro. Q J Med 1994; 87:311-314.
36. Kurokawa T, Nonami T, Kobayashi H, et al. Inhibition by cyclosporine of the production of superoxide radicals [letter]. N Engl J Med 1992; 326:840.
37. V'lckova-Laskoska MT, Laskoski DS, Caca-Biljanovska NG, Darkoska JS. Pyoderma gangrenosum successfully treated with cyclosporin A. In: Mallia C, Uitto J, editors. Rheumaderm: Current issues in rheumatology and dermatology. New York: Kluwer Academic/Plenum Publishers; 1997-1999.
38. Gul A, Esin S, Dilsen N, et al. Immunohistology of skin pathergy reaction in Behçet's disease. Br J Dermatol 1995; 132:901-907.
39. Das KM, Vecchi M, Sakamaki S. A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody. Gastroenterology 1990; 98:464-469.
40. Zonana-Nacach A, Jimenez-Balderas FJ, Martinez-Osuna P, et al. Intravenous cyclophosphamide pulses in the treatment of pyoderma gangrenosum associated with rheumatoid arthritis: Report of 2 cases and review of the literature. J Rheumatol 1994; 21:1352-1356.
41. Byrne JP, Hewitt M, Summerly R. Pyoderma gangrenosum associated with active chronic hepatitis: Report of two cases. Arch Dermatol 1976; 112:1297-301.
42. Marshall AW, Slonim JM, Smallwood RA, Fraser KJ. The association of chronic active hepatitis with pyoderma gangrenosum. Aust N Z J Med 1978; 8:656-658.
43. Burns DA, Sarkany I. Active chronic hepatitis and pyoderma gangrenosum: Report of a case. Clin Exp Dermatol 1979; 4:465-469.
44. Green LK, Hebert AA, Jorizzo JL, et al. Pyoderma gangrenosum and chronic persistent hepatitis. J Am Acad Dermatol 1985; 13:892-897.
45. Keane FM, MacFarlane CS, Munn SE, Higgins EM. Pyoderma gangrenosum and hepatitis C virus infection. Br J Dermatol 1998; 139:924-925.
46. Perry HO. Pyoderma gangrenosum. South Med J 1969; 62:899-908.
47. Hickman JG, Lazarus GS. Pyoderma gangrenosum: A reappraisal of associated systemic diseases. Br J Dermatol 1980; 102:235-237.
48. Holt PJ, Davies MG, Saunders KC, Nuki G. Pyoderma gangrenosum: Clinical and laboratory findings in 15 patients with special reference to polyarthritis. Medicine (Baltimore) 1980; 59:114-133.
49. Schoetz DJ, Jr, Coller JA, Veidenheimer MC. Pyoderma gangrenosum and Crohn's disease: Eight cases and a review of the literature. Dis Colon Rectum 1983; 26:155-158.
50. Farmer RG, Hawk WA, Turnbull RB, Jr. Clinical patterns in Crohn's disease: A statistical study of 615 cases. Gastroenterology 1975; 68:627-635.
51. Vadillo M, Jucgla A, Podzamczer D, et al. Pyoderma gangrenosum with liver, spleen and bone involvement in a patient with chronic myelomonocytic leukaemia. Br J Dermatol 1999; 141:541-543.
52. Kasuga I, Yanagisawa N, Takeo C, et al. Multiple pulmonary nodules in association with pyoderma gangrenosum. Respir Med 1997; 91:493-495.
53. Powell FC, Perry HO. Pyoderma gangrenosum in childhood. Arch Dermatol 1984; 120:757-761.
54. Omidi CJ, Siegfried EC. Chronic recurrent multifocal osteomyelitis preceding pyoderma gangrenosum and occult ulcerative colitis in a pediatric patient. Pediatr Dermatol 1998; 15:435-438.
55. Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: Classification and management. J Am Acad Dermatol 1996; 34:395-409.
56. Johnson ML, Grimwood RE. Leukocyte colony-stimulating factors. A review of associated neutrophilic dermatoses and vasculitides. Arch Dermatol 1994; 130:77-81.
57. Gangaram HB, Tan LP, Gan AT, et al. Pyoderma gangrenosum following treatment with isotretinoin. Br J Dermatol 1997; 136:636-637.
58. Perry HO, Winkelmann RK. Bullous pyoderma gangrenosum and leukemia. Arch Dermatol 1972; 106:901-905.
59. O'Loughlin S, Perry HO. A diffuse pustular eruption associated with ulcerative colitis. Arch Dermatol 1978; 114:1061-1064.
60. Peachey RD. Proceedings: Pyoderma gangrenosum of scalp. Br J Dermatol 1974; 90:106-108.
61. Futami H, Kodaira M, Furuta T, et al. Pyoderma gangrenosum complicating ulcerative colitis: Successful treatment with methylprednisolone pulse therapy and cyclosporine. J Gastroenterol 1998; 33:408-411.
62. Braverman IM. Skin signs of systemic disease. Philadelphia (PA): W.B. Sunders; 1981.
63. Levin MD, Ritchie JK, Lennard-Jones JE, Phillips RK. Pyoderma gangrenosum in inflammatory bowel disease. Br J Surg 1991; 78:676-678.
64. Cox NH, Peebles-Brown DA, MacKie RM. Pyoderma gangrenosum occurring 10 years after proctocolectomy for ulcerative colitis. Br J Hosp Med 1986; 36:363.
65. Chan YC, Valenti D, Mansfield AO, Stansby G. Warfarin induced skin necrosis. Br J Surg 2000; 87:266-272.
66. Cox C, Nowicky D, Young R. Hydroxyurea-related ankle ulcers in patients with myeloproliferative disorders: A case report and review of the literature. Ann Plast Surg 1997; 39:546-549.
67. Best PJ, Daoud MS, Pittelkow MR, Petitt RM. Hydroxyurea-induced leg ulceration in 14 patients. Ann Intern Med 1998; 128:29-32.
68. Weinlich G, Schuler G, Greil R, et al. Leg ulcers associated with long-term hydroxyurea therapy. J Am Acad Dermatol 1998; 39:372-374.
69. Sirieix ME, Debure C, Baudot N, et al. Leg ulcers and hydroxyurea: Forty-one cases. Arch Dermatol 1999; 135:818-820.
70. Velez A, Garcia-Aranda JM, Moreno JC. Hydroxyurea-induced leg ulcers: Is macroerythrocytosis a pathogenic factor? J Eur Acad Dermatol Venereol 1999; 12:243-244.
71. Stagno F, Guglielmo P, Consoli U, et al. Successful healing of hydroxyurea-related leg ulcers with topical granulocyte-macrophage colony-stimulating factor. Blood 1999; 94:1479-1480.
72. Ravandi-Kashani F, Cortes J, Cohen P, et al. Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders. Leuk Lymphoma 1999; 35:109-118.
73. Bader U, Banyai M, Boni R, et al. Leg ulcers in patients with myeloproliferative disorders: Disease- or treatment-related? Dermatology 2000; 200:45-48.
74. Flores F, Eaglstein WA, Kirsner RS. Hydroxyurea-induced leg ulcers treated with Apligraf. Ann Intern Med 2000; 132:417-418.
75. Salm RJ, Fee MJ, Giacopelli JA, et al. Brown recluse spider bite. Two case reports and review. J Am Podiatr Med Assoc 1998; 88:37-41.
76. Vaillant L, Body S, Grangeponte MC, et al. Leg ulcer of the pyoderma gangrenosum type. Manifestation of tertiary cutaneous syphilis. Ann Dermatol Venereol 1987; 114:699-702.
77. Shah B, Smith SP 3rd, Siegle RJ. North American blastomycosis: The importance of a differential diagnosis. Cutis 1996; 58:402-404.
78. Herwaldt BL, Stokes SL, Juranek DD. American cutaneous leishmaniasis in U.S. travelers. Ann Intern Med 1993; 118:779-784.
79. Arasi R, McKay M, Grist WJ. Trigeminal trophic syndrome. Laryngoscope 1988; 98:1330-1333.
80. Jemec GB, Konradsen L. Pyoderma gangrenosum complicated by necrotizing fasciitis. Cutis 1994; 53:139-140.
81. Selva A, Ordi J, Roca M, et al. Pyoderma-gangrenosum-like ulcers associated with lupus anticoagulant. Dermatology 1994; 189:182-184.
82. Magro C, Crowson AN, Mihm M, Jr. Cutaneous manifestations of nutritional deficiency states and gastrointestinal disease. In: Elder D, Elenitsas R, Jaworsky C, Johnson B, Jr, editors. Lever's histopathology of the skin. 8th ed. Philadelphia (PA): Lippincott-Raven; 1997.
83. Wolff K, Stingl G. Pyoderma gangrenosum. In: Freedberg IM, Eisen AZ, Wolff K, et al, editors. Fitzpatrick's dermatology in general medicine. New York: McGraw Hill; 1999.
84. Chow RK, Ho VC. Treatment of pyoderma gangrenosum J Am Acad Dermatol 1996; 34:1047-1060.
85. Johnson RB, Lazarus GS. Pulse therapy. Therapeutic efficacy in the treatment of pyoderma gangrenosum. Arch Dermatol 1982; 118:76-84.
86. Prystowsky JH, Kahn SN, Lazarus GS. Present status of pyoderma gangrenosum. Review of 21 cases. Arch Dermatol 1989; 125:57-64.
87. White KP, Driscoll MS, Rothe MJ, Grant-Kels JM. Severe adverse cardiovascular effects of pulse steroid therapy: Is continuous cardiac monitoring necessary? J Am Acad Dermatol 1994; 30:768-773.
88. Wolverton SE, Wilkin SK. Systemic drugs for skin disease, Philadelphia (PA): W.B. Saunders; 1991.
89. Dolan OM, Burrows D, Walsh M. Pyoderma gangrenosum of the breast treated with low-dose cyclosporin A. Clin Exp Dermatol 1997; 22:92-95.
90. Carp JM, Onuma E, Das K, Gottlieb AB. Intravenous cyclosporine therapy in the treatment of pyoderma gangrenosum secondary to Crohn's disease. Cutis 1997; 60:135-138.
91. Kavanagh GM, Ross JS, Cronin E, et al. Recalcitrant pyoderma gangrenosum - two cases successfully treated with cyclosporin A. Clin Exp Dermatol 1992; 17:49-52.
92. Magid ML, Gold MH. Treatment of recalcitrant pyoderma gangrenosum with cyclosporine. J Am Acad Dermatol 1989; 20:293-294.
93. Elgart G, Stover P, Larson K, et al. Treatment of pyoderma gangrenosum with cyclosporine: Results in seven patients, J Am Acad Dermatol 1991; 24:83-86.
94. Nousari HC, Lynch W, Anhalt GJ, Petri M. The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch Dermatol 1998; 134:1509-1511.
95. Hohenleutner U, Mohr VD, Michel S, Landthaler M. Mycophenolate mofetil and cyclosporin treatment for recalcitrant pyoderma gangrenosum [letter]. Lancet 1997; 350:1748.
96. Lyon CC, Kirby B, Griffiths C. Recalcitrant pyoderma gangrenosum treated with systemic tacrolimus. Br J Dermatol 1999; 140:562-564.
97. Jolles S, Niclasse S, Benson E. Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. Br J Dermatol 1999; 140:564-565.
98. Reich K, Vente C, Neumann C. Topical tacrolimus for pyoderma gangrenosum. Br J Dermatol 1998; 139:755-757.
99. Rustin MH, Gilkes JJ, Robinson TW. Pyoderma gangrenosum associated with Behçet's disease: Treatment with thalidomide. J Am Acad Dermatol 1990; 23:941-944.
100. Munro CS, Cox NH. Pyoderma gangrenosum associated with Behçet's syndrome - response to thalidomide. Clin Exp Dermatol 1988; 13:408-410.
101. Clemmensen OJ, Olsen PZ, Andersen KE. Thalidomide neurotoxicity. Arch Dermatol 1984; 120:338-341.
102. Wolf R. Nicotine for pyoderma gangrenosum. Arch Dermatol 1998; 134:1071-1072.
103. Bulvik S, Jacobs P. Pyoderma gangrenosum in myelodysplasia responding to granulocyte macrophage-colony stimulating factor (GM-CSF). Br J Dermatol 1997; 136:637-638.
104. Shpiro D, Gilat D, Fisher-Feld L, et al. Pyoderma gangrenosum successfully treated with perilesional granulocyte-macrophage colony stimulating factor. Br J Dermatol 1998; 138:368-369.
105. Kaplan B, Trau H, Sofer E, et al. Treatment of pyoderma gangrenosum with clofazimine. Int J Dermatol 1992; 31:591-593.
106. Callen JP, Case JD, Sager D. Chlorambucil - an effective corticosteroid-sparing therapy for pyoderma gangrenosum. J Am Acad Dermatol 1989; 21:515-519.
107. Dwarakanath AD, Yu LG, Brookes C, et al. 'Sticky' neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis. Gut 1995; 37:585-588.
108. Jacobs P, Palmer S, Gordon-Smith EC. Pyoderma gangrenosum in myelodysplasia and acute leukaemia. Postgrad Med J 1985; 61:689-694.